Risk Factors for Tumor Recurrence in Patients With Early-Stage (Stage I and II) Non-small Cell Lung Cancer Patient Selection Criteria for Adjuvant Chemotherapy According to the Seventh Edition TNM Classification

被引:77
作者
Maeda, Ryo [1 ]
Yoshida, Junji [1 ]
Ishii, Genichiro [2 ]
Hishida, Tomoyuki [1 ]
Nishimura, Mitsuyo [1 ]
Nagai, Kanji [1 ]
机构
[1] Natl Canc Ctr Hosp E, Dept Thorac Oncol, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr Hosp E, Dept Pathol, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan
关键词
LYMPH-NODE INVOLVEMENT; VINORELBINE PLUS CISPLATIN; PROGNOSTIC-SIGNIFICANCE; N1; DISEASE; CARCINOMA; SURVIVAL; RESECTION; ADENOCARCINOMA; METASTASES; COMPONENT;
D O I
10.1378/chest.10-3279
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: The purpose of this study was to evaluate risk factors for tumor recurrence in patients with completely resected early-stage non-small cell lung cancer (NSCLC). Methods: Between July 1992 and December 2007, 1,967 consecutive patients with stage I and II NSCLC with diagnoses based on the seventh edition TNM classification underwent complete resection. All patients were divided into three groups according to the stage and presence of lymph node metastasis: stage I, patients with stage I, T1-T2aN0M0 disease; stage IIN0, patients with stage II, T2b-T3N0M0, node-negative disease; and stage IIN1, patients with stage II, T1-2N1M0, node-positive disease. Freedom from recurrence rate was estimated using the Kaplan-Meier method, and recurrence risk factors were identified by univariate and multivariate analyses. Results: The 5-year freedom from recurrence rates for stage I, stage IIN0, and stage IIN1 patients were 84%, 61%, and 54%, respectively. By multivariate analyses, three variables (histologic differentiation, vessel invasion, and visceral pleural invasion) in stage I and two variables (adenocarcinoma histology and visceral pleural invasion) in stage IIN0 and stage IIN1 were shown to be independently significant risk factors for recurrence. According to subgroup analyses that combined these risk factors in each group, the 5-year freedom from recurrence rate was 63% for stage I with three risk factors, whereas those for stage IIN0 and stage IIN1 without risk factors were 83% and 78%, respectively. Conclusion: In patients with stage I and II NSCLC, we identified risk factors for recurrence. When these factors are combined, high- and low-risk subgroups can be identified within each group. CHEST 2011; 140(6):1494-1502
引用
收藏
页码:1494 / 1502
页数:9
相关论文
共 31 条
  • [1] Bronchioloalveolar Carcinoma (Lepidic Growth) Component Is a More Useful Prognostic Factor than Lymph Node Metastasis
    Anami, Yoichi
    Iijima, Tatsuo
    Suzuki, Kenji
    Yokota, Jun
    Minami, Yuko
    Kobayashi, Hiromi
    Satomi, Kaishi
    Nakazato, Yoshimasa
    Okada, Masafumi
    Noguchi, Masayuki
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (08) : 951 - 958
  • [2] [Anonymous], 2004, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs
  • [3] Where is the boundary between N1 and N2 stations in lung cancer?
    Asamura, H
    Suzuki, K
    Kondo, H
    Tsuchiya, R
    [J]. ANNALS OF THORACIC SURGERY, 2000, 70 (06) : 1839 - 1845
  • [4] A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer
    De Pas, Tommaso
    Raimondi, Sara
    Pelosi, Giuseppe
    Spaggiari, Lorenzo
    De Braud, Fillipo
    Veronesi, Giulia
    Maisonneuve, Patrick
    [J]. ACTA ONCOLOGICA, 2010, 49 (04) : 480 - 484
  • [5] Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]):: a randomised controlled trial
    Douillard, Jean-Yves
    Rosell, Rafael
    De Lena, Mario
    Carpagnano, Francesco
    Ramlau, Rodryg
    Gonzales-Larriba, Jose Luis
    Grodzki, Tornasz
    Pereira, Jose Rodrigues
    Le Groumellec, Alain
    Lorusso, Vito
    Clary, Claude
    Torres, Antonio J.
    Dahabreh, Jabrail
    Souquet, Pierre-Jean
    Astudillo, Julio
    Fournel, Pierre
    Artal-Cortes, Angel
    Jassem, Jacek
    Koubkova, Leona
    His, Patricia
    Riggi, Marcella
    Hurteloup, Patrick
    [J]. LANCET ONCOLOGY, 2006, 7 (09) : 719 - 727
  • [6] The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
    Goldstraw, Peter
    Crowley, John
    Chansky, Kari
    Giroux, Dorothy J.
    Groome, Patti A.
    Rami-Porta, Ramon
    Postmus, Pieter E.
    Rusch, Valerie
    Sobin, Leslie
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 706 - 714
  • [7] Prognostic value of bronchiolo-alveolar carcinoma component of small lung adenocarcinoma
    Higashiyama, M
    Kodama, K
    Yokouchi, H
    Takami, K
    Mano, M
    Kido, S
    Kuriyama, K
    [J]. ANNALS OF THORACIC SURGERY, 1999, 68 (06) : 2069 - 2073
  • [8] Intentional limited resection for selected patients with T1 N0 M0 non-small-cell lung cancer: A single-institution study
    Kodama, K
    Doi, O
    Higashiyama, M
    Yokouchi, H
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1997, 114 (03) : 347 - 353
  • [9] Intentional limited pulmonary resection for peripheral T1 NO MO small-sized lung cancer
    Koike, T
    Yamato, Y
    Yoshiya, K
    Shimoyama, T
    Suzuki, R
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 125 (04) : 924 - 928
  • [10] Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    Le Chevalier, T
    Arriagada, R
    Le Péchoux, C
    Grunenwald, D
    Dunant, A
    Pignon, JP
    Tarayre, M
    Abratt, R
    Arriagada, R
    Bergman, B
    Gralla, R
    Grunenwald, D
    Le Chevalier, T
    Orlowski, T
    Papadakis, E
    Pinel, MIS
    Araujo, C
    Della Torre, H
    de Solchaga, MM
    Abdi, E
    Blum, R
    Ball, D
    Basser, R
    De Boer, R
    Bishop, J
    Brigham, B
    Davis, S
    Fox, D
    Richardson, G
    Wyld, D
    Pirker, R
    Humblet, Y
    Delaunois, L
    Van Meerbeeck, JP
    Germonpre, P
    Vansteenkiste, J
    Nackaerts, K
    Pinel, MIS
    Vauthier, G
    Younes, RN
    Arriagada, R
    Baeza, R
    Carvajal, P
    Kleinman, S
    Orlandi, L
    Castro, C
    Godoy, J
    Kosatova, K
    Gaafar, R
    Azarian, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (04) : 351 - 360